In the last decade, recombinant DNA technologies have allowed the production of highly purified interferons in virtually unlimited amounts. Therefore it has become possible to evaluate the usefulness of interferon therapy in several different diseases. Nowadays interferons have a well defined role in the therapy of infectious and malignant diseases. As these natural modifiers of biological responses are widely available to the specialist and to the general practitioner as well, in the present paper we review the main biochemical properties and the molecular mechanisms underlying the heterogeneous activities of the interferons. Furthermore, on the basis of already published therapeutical trials, we indicate the infectious and neoplastic diseases in which therapy with interferon has been effective and outline the most frequent toxic or side effects of this therapy.
Get full access to this article
View all access options for this article.
References
1.
IsaacsA.LindenmannJ., 1957. Virus interference. 1. The interferon. Proceedings of the Royal Society. Series B: Biological Sciences147:258.
2.
PanemS.1985. The interferon crusade. Washington, The Brookings Institute.
3.
ScottG.M.TyrrellD.A.J., 1980. Interferon: Therapeutic fact or fiction for the '80s?Brit. Med. J.1:1558.
4.
YapW.TeoT.McCoyE.TanY., 1986. Rapid and transient rise to diacylglycerol concentration in Daudi cells exposed to interferon. Proc. Natl. Acad. Sci. USA83: 7765.
5.
BesanconF.BourgeadeM.F.TestaU., 1985. Inhibition of transferrin receptor expression by interferon in human lymphoblastoid cells and mitogen-induced lymphocytes. J. Biol. Chem.260:13074.
6.
PaulnockD.M.BordenE.C., 1985. Modulation of immune functions by interferons. In: Immunity to cancer. New York, Academic Press.
7.
LuciveroG.GambatesaV.CaponeN., 1988. Human T-T hybrodomas secreting lymphokines that modulate proliferation and differentiation of lymphoid B cells. Ital. J. Med.4:55.
8.
RossiG.B.1985. Interferon and cell differentiation. In: GresserI. Editor, Interferon, Vol. 6, New York, Academic Press.
9.
ClemensM.1985. Inteferons and oncogenes. Nature313: 531.
10.
VilcekJ.KelkeH.C.JummingY.K.YipY.K., 1985. Structure and function of human inteferon gamma. In: FordR.J. Editor, Mediators in cell growth and differentiation. New York, Raven Press.
11.
SennC.C.1984. Biochemical pathways in interferon action. Pharmacol. Ther.24:235.
12.
PaulnokD.M.BordenE.C., 1985. Modulation of immune functions by interferons. In: Immunity to cancer. New York, Academic Press.
13.
TrinchieriG.PerussiaB., 1985. Immune interferon: A pleiotropic lymphokine with multiple effects. Immunol. Today6: 131.
14.
QuesadaJ.R.HershE.M.RuebenJ.GuttermanJ.U., 1984. Alpha-interferon for induction of remission in hairy cell leukemia. N. Eng. J. Med.310:15
15.
BonomoL.CasatoM.AfeltraA.CaccavoD., 1987. Treatment of idiopathic mixed cryoglobulinemia with alfa interferon. Am. J. Med.83:726.
16.
MandelliF.AvvisatiG.AmadoriS.BoccadoroM.GernoneA.LautaV.M.MarmontF.PetrucciM.T.TribaltoM.VegnaM.L.DammaccoF.PileriA., 1990. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med.322:1430.
17.
TalpazM.KantarjianH.McCredieK.KeatingM.TrujilloJ.M.KeatingM.J.GuttermanJ.U., 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N. Engl. J. Med.314:1065.
18.
TuraS.MazzaP.ZinganiP.L.GhettiP.L.PolettiG.GherlinzoniF.MontagnaniA.CriscuoloD., 1987. Alpha recombinant interferon in the treatment of mycosis fungoides. Haematologica72: 337.
19.
GisslingerH.LudwigH.LinkeschW.ChottA.FritzE.RadaszkiewiczT.H., 1989. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet1: 634.
20.
WhiteC.W.SondheimerH.M.CrouchE.C.WilsonH.FanL.L., 1989. Treatment of pulmonary hemangiomatosis with recombinant anterferon alpha-2a. N. Engl. J. Med.320: 1197.
21.
HealyG.B.GelberR.D.TrowbridgeA.L.GrundfastK.M.RubenR.J.PriceK.N., 1988. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N. Engl. J. Med.319:401.
22.
SchonfeldA.SchattnerA.CrespiM., 1984. Intramuscolar human interferon-beta injections in treatment of condylomata acuminata. Lancet1: 1038.
23.
BadaroR.FalcoffE.BadaroF.S.CarvalhoE.M.Pedral-SampaioD.BarralA.CarvalhoJ.S.Barral-NettoM.BrandelyM.SilvaL.BinaJ.C.TeixeiraR.FalcoffR.RochaH.HoJ.L.JohnsonW.D.Jr, 1990. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med.322:16.
24.
KirkwoodJ.M.ErnstoffM.S.DavisC.A.1985. Comparison of intramuscolar and intravenous recombinant alfa-2 interferon in melanoma and other cancers. Ann. Intern. Med.103:32.
25.
De WitR.SchattenkerkJ.K.M.E.BoucherC.A.B.BakkerP.J.M.VeenhofK.H.N.DannerS.A., 1988. Clinical and virological effects of high dose recombinant interferon-α in disseminated AIDS-related Kaposi's sarcoma. Lancet2: 1214.
26.
VugrinD.HoodL.LaszloJ., 1985. A phase II trial of high dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma. Cancer Treat. Rep.69:817.
27.
Di BisceglieA.M.MartinP.KassianidesC.Lisker-MelmanM.MurrayL.WaggonerJ.GoodmanZ.BanksS.M.HoofnagleJ.H., 1989. Recombinat interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med.321:1506.
28.
DeytonL.R.WalkerR.E.KovacsJ.A.HerpinB.ParkerM.MasurH.FauciA.S.LaneH.C., 1989. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N. Engl. J. Med.321:1246.
29.
SilverH.K.B.ConnorsJ.M.SalinasF.A., 1985. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon. Cancer. Treat. Rep.69:743.
30.
AdamsF.QuesadaJ.R.GuttermanJ.U., 1984. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J. Am. Med. Assoc.252:938.
31.
SteisR.G.SmithJ.W.UrbaW.J.ClarkJ.W.ItriL.M.EvansL.M.SchoenbergerC.LongoD.L., 1988. Resistance to recombinant inteferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med.318:1409.
